Ozempic Face: What It Is, Why It Happens, and What the Evidence Says

“Ozempic face” is a media term, not a diagnosis. It describes a face that looks thinner, hollower or saggier after losing a lot of weight on semaglutide (Ozempic, Wegovy) or tirzepatide (Zepbound, Mounjaro). What we know points to the weight loss itself, not to the drug acting on your skin: when you lose weight, you lose fat from your face too, and with age, skin bounces back less^[2]. No US or EU label mentions loss of facial fat^{[6,7,8,9,10,11]}, and I haven’t found any trial that measures it.

Where the term comes from

The phrase took off with a New York Times article published January 24, 2023. It described people asking for facial fillers after losing weight on these drugs^[1]. It’s journalism: it reports what doctors were seeing, without measuring anything.

The evidence is still thin. A 2025 systematic review gathered 23 publications on these drugs and the face, almost all in plastic or aesthetic surgery journals. Only 3 were cohort studies with a comparison group. Of the rest, one was a survey of surgeons, one a systematic review, and the others letters, reviews, opinion pieces and case reports. The authors point out that there’s no proof these drugs reduce fat in the face more than anywhere else^[2].

The same review notes that in the US, searches for “Ozempic face” rose at the same time as searches for “facial filler” and “plastic surgeon”. It adds that many companies already sell products aimed at these effects, which is worth keeping in mind as you read about the topic^[2].

Why your face changes when you lose weight

Your face isn’t one solid block. A classic anatomy study by Rohrich and Pessa (2007) showed that the fat under facial skin sits in separate compartments: forehead, temples, around the eyes, cheeks, the fold between nose and mouth (the nasolabial fold) and the jawline. The authors link part of facial aging to how these compartments change over time^[3].

When you lose a lot of weight, those compartments lose volume too. According to the 2025 review, losing fat in the temples, cheeks, under the eyes, along the jawline and in the folds around the mouth and nose can give a gaunt look that resembles accelerated aging^[2].

Age shifts the balance:

• Skin has less collagen as the years go by. Collagen is the protein that keeps skin firm, and in a classic study it declined with age and was lower in women at every age^[5]. The 2025 review notes that facial changes after weight loss are more marked in older people, who have less collagen^[2].
• Weight doesn’t “age” you the same way at every age. In 186 pairs of identical twins, a body mass index (BMI) 4 points higher was linked to looking older before age 40, but younger after 40^[4]. Past a certain age, some facial fat hides the years.

None of this is unique to GLP-1 medications. Some authors cited in the 2025 review argue that these drugs don’t target facial fat at all: they reveal age-related laxity that a thicker layer of fat used to hide^[2].

Does the drug act directly on your skin?

According to the labels, there’s no sign of it. I went through the adverse reactions in the US prescribing information for Wegovy, Zepbound and Ozempic, and in the EU prescribing information for Wegovy, Mounjaro and Ozempic. None of them mentions loss of facial fat or skin aging. The face only comes up as a place where swelling can appear during a serious allergic reaction^{[6,7,8,9,10,11]}. Here’s what the US labels do report that relates to skin and hair:

US labels checked on September 23, 2026 (Wegovy revised 6/2026, Zepbound revised 8/2026, Ozempic in its June 2026 DailyMed version)^[6,7,8]. The 7.2 mg figures come from separate trials with their own 2.4 mg group. The Wegovy label adds that altered skin sensation became more frequent as the dose, and drug levels in the blood, went up^[6].

The EU prescribing information pools the trials differently. For Wegovy, it reports hair loss in 2.5% vs. 1.0% on placebo with 2.4 mg, 5.3% vs. 1.0% with 7.2 mg, and 6.4% vs. 2.0% with the tablets^[9]. The US label doesn’t break out hair loss for the tablets; it says their common side effects were similar to the injection’s^[6]. For altered skin sensation, the EU figures are 2.1% vs. 1.2% with 2.4 mg and 21.6% vs. 0.3% with 7.2 mg^[9]. For tirzepatide, sold in the EU as Mounjaro for both diabetes and weight management, hair loss is “common” (between 1 and 10 in 100 people), mainly in people with overweight or obesity, and altered skin sensation is “uncommon” (between 1 and 10 in 1,000)^[10]. The EU information for Ozempic doesn’t list hair loss, and lists changes in skin sensation with a frequency that can’t be estimated^[11].

The Zepbound label also reports hypersensitivity (allergic) reactions in 5% of people at each dose vs. 3% on placebo in the weight-reduction trials, most of them skin reactions such as rash or itching^[7]. The EU prescribing information for Mounjaro gives 5.0% vs. 3.8% on placebo in the weight-management trials, sometimes severe (for example, hives, eczema, rash or dermatitis)^[10].

How much weight people lose in the trials, and how fast

In STEP 1, half of the people on semaglutide (50.5%) lost at least 15% of their weight^[12]. In SURMOUNT-1, 57% of those on 15 mg lost at least 20%^[13].

The average pace is slower than people tend to think. My own math: 15.3 kg over 68 weeks is about 0.2 kg (0.5 lb) a week; 20.9% of 104.8 kg over 72 weeks is about 0.3 kg (0.7 lb) a week. The UK’s National Health Service suggests 0.5 to 1 kg (1 to 2 lb) a week as a general goal^[16]. These are averages, and everyone moves at their own pace. The EU prescribing information for Wegovy adds that in the two-year STEP 5 trial, average weight went down until week 68 and then leveled off^[9].

My reading: what sets these drugs apart is the total amount of weight lost more than the speed. According to the 2025 review, people usually lose at most about 25% of their weight with medication. That’s less than the massive losses after bariatric surgery, but some of the same volume and skin problems show up^[2].

Hair loss: what the labels say, and what telogen effluvium is

The US labels for Wegovy and Zepbound both say hair loss was associated with weight reduction^[6,7]. Both report it more often in women: 4% of women and 0.9% of men on Wegovy 2.4 mg^[6], and 7.1% of women vs. 0.5% of men on Zepbound, where no one stopped treatment because of it^[7].

The EU prescribing information for Wegovy adds details the US label doesn’t give. With the injection, hair loss was mostly mild, more frequent in people who lost 20% of their weight or more, and most people recovered while staying on treatment. With the tablets, about half of the cases resolved before the trial ended^[9].

All of this is consistent with telogen effluvium: diffuse, non-scarring and usually temporary hair shedding. After a trigger, such as physical stress or calorie restriction, many hair follicles enter their resting phase early, and the hair falls out about two to three months later^[32]. It isn’t unique to these drugs:

• In a 2024 Korean dermatology study of 140 people with telogen effluvium after weight loss, the average loss was 15.2% of body weight, at 3.5 kg (7.7 lb) a month. Everyone improved, on average within 4.8 months, without treatment. Women developed it while losing weight more slowly than men did, and older people with smaller losses. It’s a retrospective study, based on weights the patients recalled^[17].
• After bariatric surgery, a 2025 meta-analysis of 41 studies with 7,044 patients estimates that 47% had hair loss^[18].

The 2025 joint advisory from four US obesity and nutrition societies lists excessive hair shedding among the signs of possible nutrient deficiency, along with flaky skin and unusual tiredness^[19]. If you notice them, talk to your doctor.

If the shedding worries you, my guide to hair loss on Ozempic, Wegovy, Zepbound or Mounjaro covers how long it usually lasts, what eating well can do and when to see a doctor.

Ozempic body: loose skin and body-shape changes after weight loss

“Ozempic body” is a colloquial term, not a medical one. Loose skin has its own guide, with the biopsy studies and what helps and what doesn’t: loose skin after weight loss on a GLP-1. People use it for loose skin on the belly, arms or thighs, and for shape changes such as a flatter behind (the so-called “Ozempic butt”, covered with the breasts, feet, teeth and vulva in the next section). It isn’t a label term either: the US labels for Wegovy, Zepbound and Ozempic and the EU labels for Wegovy, Mounjaro and Ozempic don’t mention sagging skin or the buttocks^{[6,7,8,9,10,11]}.

Why skin ends up loose. A 2026 systematic review in a plastic surgery journal gathered 40 studies on these drugs and the skin. They describe thinner skin, loss of collagen and elastin fibers, and less elasticity. The review lists older age, many years with obesity, rapid weight loss, drinking too little and eating too little protein as risk factors^[25]. It mixes trials, observational studies and case reports, so its conclusions are a rough guide.

After bariatric surgery, where losses are larger than on medication, excess skin is the norm: according to a review of 24 studies, it affects more than 70% of adults who have the surgery, and women report more of it and more discomfort. It couldn’t pin down the role of age or of how much weight was lost^[26].

Where the fat comes off. The trials haven’t measured the order in which each area slims down, but they have measured which fat drops most. In the SURMOUNT-1 body-composition substudy (study summary), total fat mass fell 33.9% on tirzepatide over 72 weeks, and visceral fat, the fat around the organs in the belly, fell 40.1%^[30]. In STEP 1, on semaglutide, the figures were 19.3% and 27.4% over 68 weeks^[31]. The US labels for Wegovy and Zepbound say the drug lowers body weight with greater fat mass loss than lean mass loss^[6,7]. The skin that covered the lost fat doesn’t always pull back.

What helps and what doesn’t:

• The pace of weight loss is up to your doctor. The 2026 review lists rapid loss as a risk factor, on weak evidence^[25]. If it worries you, bring it up at your appointment.
• Protein and strength training. The 2025 joint advisory recommends enough protein plus strength training to preserve lean mass^[19]; the numbers are in protein and muscle on GLP-1 medications. Whether they prevent loose skin hasn’t been studied.
• Creams: weak evidence. A 2026 review, with three of its seven authors employed by Allergan Aesthetics, a medical aesthetics company, only concludes that topical skincare “may be” a useful add-on to other treatments^[29]. I haven’t found independent trials of creams after major weight loss.
• Surgery is a decision to make with a specialist. Removing excess skin is major surgery. In a 2021 systematic review after bariatric surgery, only 18.5% of survey respondents had had it, although most wanted it; cost and lack of insurance coverage were the main barriers^[27]. The plastic surgery review asks for a stable weight for 3 to 6 months before surgery^[28]. Talk it through with a board-certified plastic surgeon.

When to see a doctor. If you get pain, irritation or chafing under skin folds (intertrigo, which that review calls common under large folds^[28]), talk to your doctor or a dermatologist. Do the same if loose skin limits how you move, or if worry about your body leads you to eat less than you need.

Ozempic body: butt, breasts, feet, teeth and other changes

None of these names is a diagnosis or a label term. They’re what people online call changes they notice while losing weight on semaglutide or tirzepatide. For the butt, breasts, feet and vulva, the mechanism is the same as for the face: the areas that are mostly fat lose volume, some muscle goes too (in SURMOUNT-1, about a quarter of the weight lost was lean mass^[30]), and the skin doesn’t always pull back^[25]. Teeth are the exception, with different causes. No trial has measured any of these areas in people on GLP-1 medications; where only case reports exist, I say so. What the FDA says about fillers in the buttocks, breasts and feet is in the fillers section below.

Ozempic butt

The buttocks are fat and muscle. A plastic surgery review of massive weight loss describes a “deflated appearance” that is most visible in the breasts, buttocks and face, with buttocks that sag and lose projection^[28]. Protein plus strength training is the combination with the most support for keeping lean mass^[19]; whether it changes the shape of the buttocks hasn’t been studied.

Ozempic breasts

Breasts lose volume with weight loss too. In people who lost massive amounts of weight, the same review describes breasts that deflate and flatten, sag as the skin loses elasticity, and sometimes lose volume unevenly between the two sides^[28]. Those are losses on the scale of bariatric surgery, larger than what medication usually achieves^[2]. A change in size is common with weight loss; a new lump, nipple discharge or skin changes on the breast are not part of weight loss, so get them checked by your doctor.

Ozempic feet

People use the term for feet that look bonier and for soles that feel less cushioned. Under the heel there’s a pad of fat. In an ultrasound study of 87 adults, people with overweight or obesity had thicker heel pads than people of normal weight, and thickness rose with BMI^[39]. That comparison suggests the pad could thin as weight comes off, but no study has followed feet during weight loss on GLP-1 medications.

Tingling, burning or painful skin is a different issue: the US labels list it as altered skin sensation (dysesthesia), and it’s more frequent at higher Wegovy doses (see the table above)^[6,7]. Numbness or burning in the feet, especially if you have diabetes, is worth a visit to your doctor.

Ozempic teeth

“Ozempic teeth” covers dry mouth, tooth sensitivity, enamel erosion and cavities. These drugs don’t attack enamel directly; three indirect routes are proposed:

• Dry mouth. The Zepbound label reports dry mouth or dry throat in 1% of people vs. 0.1% on placebo^[7]; the Wegovy label doesn’t list it^[6]. The American Dental Association (ADA) lists GLP-1 receptor agonists among medicines that can cause or worsen dry mouth, and explains that less saliva raises the risk of cavities, demineralization and tooth sensitivity^[34]. The first report specific to semaglutide was a case series of three women seen at an oral medicine clinic after 6 to 16 weeks of treatment; all three regained acceptable saliva flow, with management that ranged from stopping the drug to a saliva-stimulating medicine or symptom relief^[33].
• Vomiting and reflux. Stomach acid can dissolve enamel, and the ADA lists acid reflux and repeated vomiting among causes of dental erosion, a loss of tooth mineral that can’t be reversed^[35]. On Wegovy 2.4 mg, the US label reports vomiting in 24% vs. 6% on placebo and gastroesophageal reflux disease in 5% vs. 3%^[6]; on Zepbound, vomiting in 8%, 11% and 13% with 5, 10 and 15 mg vs. 2% on placebo, and reflux in 4% to 5% vs. 2%^[7]. After vomiting, the ADA advises rinsing with water, a baking soda rinse or milk instead of brushing right away^[35]. If you’re struggling with nausea, my guide on what to eat when you’re nauseous on a GLP-1 may help.
• Grazing. Eating small amounts many times a day, especially sweet snacks or drinks, exposes teeth to sugar more often. The ADA’s nutrition and oral health overview notes that how often you eat sugar has been proposed to matter more than how much, although the two are hard to separate^[36].

The evidence is thin. A 2026 letter by dental researchers concludes that evidence on these drugs’ direct effects on oral health “remains scarce”^[37]. What exists is one case series, a plausible mechanism and commentary from dental researchers. Tell your dentist which medication you’re on.

Ozempic vulva

The term describes a vulva that looks deflated or looser after weight loss. The mechanism is again fat loss: the mons pubis, the pad of fat over the pubic bone, loses volume, and the skin over it may not retract. The plastic surgery review describes the mons as almost always sagging after massive weight loss^[28]. A series of 23 women who had bariatric surgery calls sagging excess skin in the pubic area a very common deformity after massive weight loss, one that may cause distress and affect quality of life^[38]. No study has looked at this in people on GLP-1 medications. Itching, pain, sores, bleeding or urinary symptoms are not explained by fat loss; see your doctor or a gynecologist.

What has support for looking after your face and body

A caveat: no study has measured whether any of these changes the face of someone on a GLP-1. They’re supported for other reasons.

• The pace of weight loss is up to your doctor. It depends on the drug, the dose and how it’s increased. The 2025 advisory notes that the pace of weight loss affects bone loss, and calls for adjusting nutrition to that pace^[19]. If you’re worried about your face, bring it up at your appointment: it’s useful information.
• Protein and strength training. This is the combination with the most support for keeping lean mass while you lose weight. I go through the numbers in protein and muscle on GLP-1 medications, and you can estimate your own target with the protein calculator. The big picture of eating on treatment is in what to eat on GLP-1 medications.
• Daily sunscreen. It has trial evidence against skin aging. In an Australian trial of 903 adults under 55, people who used sunscreen every day showed no detectable increase in skin aging after 4.5 years, and aged 24% less than those who used it at their own discretion^[20].
• Drinking enough. The main reason is that nausea, vomiting and diarrhea can dehydrate you: the Wegovy and Zepbound Medication Guides warn that they may cause a loss of fluids (dehydration), which may cause kidney problems^[6,7]. As for skin, a systematic review found only 6 studies, all of weak quality. Drinking more may add a little moisture to the outer layer, mostly in people who drank little to begin with^[21].
• Sleep. In an experiment with 23 adults, their faces were rated as less healthy and more tired after a short night followed by 31 hours awake^[22]. It’s a small study of extreme sleep loss, and the differences were modest.

What has little or no evidence

• Collagen supplements. A 2025 meta-analysis of 23 trials with 1,474 people found improvements in hydration, elasticity and wrinkles when all the trials were pooled. But in the trials without industry funding, and in the highest-quality ones, there was no effect. The authors conclude there’s no clinical evidence to support using them against skin aging^[23]. None of the trials looked at loss of facial volume.
• Creams. I haven’t found any trials of creams in people who lost facial volume after losing weight.

Fillers for Ozempic face: what they are and what the FDA says

Dermal fillers are implants injected under the skin to add volume or smooth wrinkles. In the US they’re regulated as medical devices, and the FDA has approved them only for adults 22 and older and for specific uses. Absorbable (temporary) fillers are approved for moderate to severe facial wrinkles and folds and to add volume to the lips, cheeks, chin and back of the hand. Non-absorbable (permanent) fillers are approved only for the folds from nose to mouth and for cheek acne scars. Fillers are also approved to restore facial fat loss in people with HIV^[24]. None of these approvals is specific to weight loss.

The FDA adds that removing a filler may be difficult or impossible, especially permanent fillers or those not made of hyaluronic acid. It recommends against using any injectable filler to enlarge the breasts or buttocks or to fill out the feet, and injectable silicone isn’t approved for any cosmetic use, including body contouring^[24].

Fillers are medical procedures with risks. The FDA warns of common side effects such as bruising, swelling or pain. It also warns of rare but serious risks if the product gets into a blood vessel: tissue death, vision problems including blindness, and stroke^[24]. Treatments that tighten skin or remove it surgically carry their own risks.

I don’t recommend specific clinics or treatments here. If you’re considering one, the FDA advises going to a licensed health care provider with experience in dermatology or plastic surgery^[24]. The 2025 review points out that before cosmetic surgery, surgeons look at several factors, including whether your weight has been stable^[2].

The part the mirror doesn’t show

Watching your face change can be hard, even if you feel better on the inside, and that’s understandable. It helps to remember that “Ozempic face” is a media label, and that a thinner face isn’t a sick face.

The goal of obesity treatment is health, not a number on the scale or a particular face. If worry about how you look leads you to eat much less than you need, or to check yourself over and over, reach out for professional help: your doctor, a therapist or an eating-disorder specialist.

Frequently asked questions

Does your face go back to normal after stopping the drug?

No study has measured it. What we do know is that when treatment stops, much of the weight comes back. In the STEP 1 extension (study summary), people who had lost 17.3% of their weight regained about two-thirds of it within a year^[14]. In SURMOUNT-4 (trial summary), those switched to placebo gained 14.0% over 52 weeks^[15]. The 2025 review speculates that the gaunt look might soften as weight returns, but also notes that fat rarely redistributes the way it was before^[2]. I explain the regain side in what happens when you stop Ozempic, Wegovy or Zepbound. Whether to stop treatment is a decision to make with your doctor.

Does it only happen with Ozempic?

No. It comes with any substantial weight loss, whether from a drug, a diet or surgery.

Does it happen to everyone?

No. How much weight you lose and your age matter most. In the twin study, the effect of 4 extra BMI points on the face reversed after age 40^[4].

Is the hair loss permanent?

Usually not: with Wegovy injections, most people recovered while staying on treatment (EU prescribing information)^[9], and in the Korean study everyone improved^[17]. If the shedding is heavy or lasts a long time, talk to your doctor.

Can collagen prevent it?

There’s no evidence it does: the 2025 meta-analysis found no effect in the highest-quality trials^[23].

Does loose skin tighten on its own?

No one has measured it in people losing weight on GLP-1 medications. After bariatric surgery, where losses are larger, more than 70% of patients have excess skin according to the 2017 review^[26], and the plastic surgery review describes skin that doesn’t fully retract^[28]. The 2026 systematic review lists older age and rapid weight loss as risk factors^[25]. If it bothers you, a dermatologist or a plastic surgeon can go over the options.

Do you lose muscle on Ozempic?

Some, as with any major weight loss. In STEP 1, on semaglutide 2.4 mg (the active ingredient in Ozempic and Wegovy), lean mass fell 9.7% and fat mass 19.3%^[31]. In SURMOUNT-1, on tirzepatide, the figures were 10.9% and 33.9%: about a quarter of the weight lost was lean mass^[30]. Lean mass isn’t only muscle: the 2025 joint advisory estimates muscle is about half of it^[19]. The US labels for Wegovy and Zepbound say the drug lowers body weight with greater fat mass loss than lean mass loss^[6,7]. Enough protein plus strength training has the most support for limiting it; I go through it in protein and muscle on GLP-1 medications.

Can Ozempic damage your teeth?

Not directly, but it can create the conditions for problems. Dry mouth, vomiting and reflux all expose teeth to more acid or less saliva^[34,35]. On Wegovy 2.4 mg, 24% of people vomited, vs. 6% on placebo^[6]. The only reports specific to semaglutide are case reports, such as a series of three women with severe dry mouth^[33]. Tell your dentist which medication you take.

Is “Ozempic vulva” a real side effect?

It’s not a label term or a diagnosis: neither the US labels for Wegovy, Zepbound and Ozempic nor the EU labels for Wegovy, Mounjaro and Ozempic mention it^{[6,7,8,9,10,11]}. It describes a looser, less full vulva after fat loss, the same mechanism as the face. After massive weight loss from bariatric surgery, sagging of the pubic area is common^[28,38]. No study has measured it in people on GLP-1 medications.

Which doctor can help?

For your treatment, the person who prescribes it. For skin and hair, a dermatologist. For teeth and dry mouth, a dentist. For volume-restoring procedures or removing excess skin, a dermatologist or a plastic surgeon.